Photo courtesy of Yonhap News

 

[Alpha Biz= Kim Jisun] SEOUL, May 25 — Huons Group has strongly denied allegations that its planned merger between Huons and Huons Lab is intended to facilitate succession, amid growing concerns from 일부 shareholders.

The group said in a statement that claims linking the merger to succession plans are “completely unfounded,” emphasizing that the decision is aimed at strengthening future growth drivers and enhancing R&D competitiveness.

The merger, approved by Huons’ board on May 18, has faced backlash from some shareholders of Huons Global, who raised concerns over valuation and the transfer of future growth potential from Huons Lab to Huons. Huons Lab is currently developing its HyDIFFUZE platform technology, which enables the conversion of intravenous drugs into subcutaneous formulations.

Huons Group stressed that Huons Lab remains in a capital-impaired state and requires stable funding for continued research, while the merger would also support regulatory requirements and expanded R&D investment.

The company added that the merger structure and ratio were reviewed by external advisors and a special committee, and pledged continued communication with shareholders while considering measures to protect shareholder value.

 

 

 

[ⓒ 메디컬투데이. 무단전재-재배포 금지]